| Bioactivity | Atovaquone (Atavaquone) is a potent, selective and orally active inhibitor of the parasite’s mitochondrial cytochrome bc1 complex. Atovaquone is against human and P. falciparum cytochrome bc1 activity with IC50 values of 460 nM and 2.0 nM, respectively. Atovaquone is an antimalarial agent and has the potential for the investigation of neumocystis pneumonia, toxoplasmosis, malaria, and babesia[1][2]. | ||||||||||||
| Invitro | Atovaquone targets to the Qo site of the Plasmodium cytochrome bc1 complex of the mitochondrial electron transport chain[1].Atovaquone is against the development in the mosquito from gamete production, through fertilization, zygote formation and finally, to the development of the mature ookinete, and demonstrates an IC50 of 67 nM providing further evidence of the transmission blocking potential of this molecule[1]. | ||||||||||||
| Name | Atovaquone | ||||||||||||
| CAS | 95233-18-4 | ||||||||||||
| Formula | C22H19ClO3 | ||||||||||||
| Molar Mass | 366.84 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|